Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07356089 · ClinicalTrials.gov registry record
Twiist Postmarket Surveillance Study for Type 1 Diabetes
A clinical trial of Type 1 Diabetes Mellitus and Type 1 Diabetes (T1D), sponsored by Deka Research and Development.
- Recruiting
- Registry status
- 1,875
- Enrollment target
- 1
- Study location
NCT07356089 is a study of Type 1 Diabetes Mellitus and Type 1 Diabetes (T1D) that is actively recruiting participants, run by Deka Research and Development. The registered enrollment target is 1,875 participants, above the 122-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (1437% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07356089, a study of Type 1 Diabetes Mellitus and Type 1 Diabetes (T1D), is actively recruiting participants, sponsored by Deka Research and Development.
- RECRUITING
- Registry status
- 1,875 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this surveillance study is to collect real-world data on adults and youth with type 1 diabetes (T1D) using twiist(TM) for insulin delivery.
Conditions Studied
Interventions
- DEVICE twiist Automated Insulin Delivery System
Study Locations (1)
Florida
- Jaeb Center for Health Research - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,875 participants |
| Start Date | 2025-12-09 |
| Est. Completion | 2028-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07356089
The ClinicalTrials.gov registry entry for NCT07356089 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,875 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 122-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (1437% higher). The listed sponsor is Deka Research and Development, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which twiist Automated Insulin Delivery System is the first listed.
NCT07356089 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07356089 about?
NCT07356089 is a clinical study titled "Twiist Postmarket Surveillance Study for Type 1 Diabetes". The goal of this surveillance study is to collect real-world data on adults and youth with type 1 diabetes (T1D) using twiist(TM) for insulin delivery.
What is the current status of trial NCT07356089?
This trial is currently recruiting. The enrollment target is 1,875 participants. The study started on 2025-12-09. Estimated completion is 2028-05-01.
What conditions does trial NCT07356089 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus, Type 1 Diabetes (T1D).
What interventions are being tested in trial NCT07356089?
The interventions under investigation include: twiist Automated Insulin Delivery System (DEVICE).
Who is sponsoring clinical trial NCT07356089?
This trial is sponsored by Deka Research and Development, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07356089 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Dapagliflozin Plus Pioglitazone in T1DM
RECRUITING · Phase 4
-
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.